Cogent Biosciences, Inc. (COGT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cogent Biosciences, Inc. (COGT) Healthcare & Pipeline Overview

Cogent Biosciences is a biotechnology firm specializing in precision therapies for genetically defined diseases, with a focus on its lead candidate, CGT9486, a selective tyrosine kinase inhibitor targeting KIT mutations. The company aims to address unmet needs in systemic mastocytosis and advanced gastrointestinal stromal tumors.

What Is the Investment Thesis for COGT?

The drug's selective targeting of the KIT D816V mutation in systemic mastocytosis offers a significant value driver, addressing a critical unmet need. Upcoming clinical trial results for CGT9486 will be a key catalyst, with positive data potentially leading to accelerated regulatory pathways. The company's licensing agreement with Plexxikon Inc. for bezuclastinib further strengthens its pipeline. However, potential risks include clinical trial setbacks, regulatory hurdles, and competition from existing and emerging therapies. The company's market capitalization of $5.76B reflects investor expectations for CGT9486's success. Continued progress in clinical development and strategic partnerships will be crucial for realizing the full potential of Cogent Biosciences.

Based on FMP financials and quantitative analysis

COGT Key Highlights

Lead product candidate CGT9486 targets the KIT D816V mutation, a key driver in systemic mastocytosis.

• Licensing agreement with Plexxikon Inc. for bezuclastinib strengthens the company's pipeline.
• Market capitalization of $5.76B reflects investor confidence in the company's precision medicine approach.
• The company rebranded from Unum Therapeutics Inc. to Cogent Biosciences, Inc. in October 2020, signaling a strategic shift.
• Beta of 0.47 indicates lower volatility compared to the overall market.

Who Are COGT's Competitors?

COGT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are COGT's Key Strengths?

Focus on precision medicine and genetically defined diseases.

• Lead product candidate CGT9486 targets a specific genetic mutation.
• Licensing agreement with Plexxikon Inc. for bezuclastinib.
• Experienced management team with expertise in drug development.

What Are COGT's Weaknesses?

Reliance on a limited number of product candidates.

• High risk associated with clinical development and regulatory approval.
• Competition from established pharmaceutical companies.
• Limited commercial infrastructure.

What Could Drive COGT Stock Higher?

Clinical trial results for CGT9486 in systemic mastocytosis.

• Regulatory submissions for CGT9486.
• Expansion of CGT9486 into additional indications.
• Strategic partnerships and collaborations.

What Are the Key Risks for COGT?

Negative return on equity (-85.7%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $240.8M recently.
• Clinical trial setbacks.
• Regulatory hurdles.
• Competition from existing and emerging therapies.
• Patent challenges.
• Reliance on key personnel.

What Are the Growth Opportunities for COGT?

• Expansion into Additional Indications: Cogent Biosciences has the opportunity to expand the application of CGT9486 beyond systemic mastocytosis and advanced GIST. Given its mechanism of action as a selective tyrosine kinase inhibitor, CGT9486 could potentially be effective in treating other diseases driven by KIT mutations. This expansion could significantly increase the addressable market and revenue potential. The timeline for exploring new indications depends on ongoing research and clinical trial results, but represents a long-term growth driver for the company. The market size for additional KIT-driven diseases could reach billions of dollars.
• Strategic Partnerships and Collaborations: Cogent Biosciences can pursue strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to accelerate the development and commercialization of its therapies. Collaborations could provide access to new technologies, funding, and market expertise. The company's existing licensing agreement with Plexxikon Inc. demonstrates its ability to forge successful partnerships. The timeline for securing new partnerships is ongoing, with potential deals emerging as clinical programs advance. Strategic partnerships could unlock significant value and expand Cogent's reach.
• Advancements in Diagnostic Technologies: The increasing availability and sophistication of diagnostic technologies, such as genetic sequencing, are driving the adoption of precision medicine. As diagnostic tools become more accessible and affordable, more patients will be identified with genetically defined diseases that can be targeted by therapies like CGT9486. This trend will expand the market for Cogent Biosciences' products and services. The timeline for widespread adoption of advanced diagnostics is ongoing, with continuous improvements in technology and decreasing costs. This trend represents a long-term growth driver for the company.
• Regulatory Pathway Optimization: Cogent Biosciences can optimize its regulatory strategy to expedite the approval of its therapies. By leveraging accelerated approval pathways, such as breakthrough therapy designation and priority review, the company can potentially bring its products to market faster. A streamlined regulatory pathway can significantly reduce development costs and increase the return on investment. The timeline for regulatory approval depends on clinical trial results and interactions with regulatory agencies, but proactive engagement can improve the likelihood of success. Efficient regulatory strategies are crucial for maximizing the value of Cogent's pipeline.
• Commercialization and Market Access: Successful commercialization and market access are essential for realizing the full potential of Cogent Biosciences' therapies. The company needs to develop a robust commercial infrastructure and secure favorable reimbursement from payers. Effective marketing and sales strategies will be critical for driving adoption and generating revenue. The timeline for commercialization depends on regulatory approval and market readiness, but proactive planning can ensure a successful launch. Strong commercial execution is crucial for maximizing the financial returns from Cogent's innovative therapies.

What Are COGT's Competitive Advantages?

• Proprietary technology targeting specific genetic mutations.
• Licensing agreements for key therapeutic candidates.
• Strong focus on precision medicine and genetically defined diseases.

What Does COGT Do?

Cogent Biosciences, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, is a biotechnology company dedicated to creating precision therapies for genetically defined diseases. Originally incorporated as Unum Therapeutics Inc., the company rebranded in October 2020 to reflect its refined strategic focus. Cogent's primary focus is on developing innovative treatments that target the underlying genetic drivers of diseases, with an initial emphasis on systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST). Their lead product candidate, CGT9486 (bezuclastinib), is a selective tyrosine kinase inhibitor specifically designed to inhibit the KIT D816V mutation, which is a primary driver of systemic mastocytosis. Additionally, CGT9486 targets other mutations in KIT exon 17, relevant in treating patients with advanced GIST. Cogent Biosciences operates under a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib, strengthening its position in the precision medicine landscape. The company's evolution from Unum Therapeutics to Cogent Biosciences signifies a strategic shift towards more targeted therapies and a commitment to addressing unmet medical needs in genetically defined diseases. Cogent's approach involves rigorous scientific research and clinical development to bring potentially transformative treatments to patients.

What Products and Services Does COGT Offer?

• Develop precision therapies for genetically defined diseases.
• Focus on treatments targeting specific genetic mutations.
• Lead product candidate is CGT9486, a selective tyrosine kinase inhibitor.
• Target the KIT D816V mutation in systemic mastocytosis.
• Address mutations in KIT exon 17 found in advanced gastrointestinal stromal tumors (GIST).
• Engage in research and clinical development to advance their pipeline.
• Collaborate with other companies through licensing agreements.

How Does COGT Make Money?

• Develop and commercialize precision therapies for genetically defined diseases.
• Focus on licensing agreements for research, development, and commercialization of therapies.
• Generate revenue through the sale of approved therapies.

What Industry Does COGT Operate In?

Cogent Biosciences operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory scrutiny. The precision medicine segment, where Cogent focuses, is experiencing significant growth driven by advancements in genomics and targeted therapies. The competitive landscape includes companies developing similar kinase inhibitors and other targeted treatments for genetically defined diseases. Cogent's success depends on its ability to demonstrate clinical efficacy, navigate regulatory pathways, and secure market access for its therapies. The biotechnology industry is projected to continue growing, fueled by increasing demand for personalized medicine and innovative treatments.

Who Are COGT's Key Customers?

• Patients with systemic mastocytosis.
• Patients with advanced gastrointestinal stromal tumors (GIST).
• Healthcare providers who prescribe and administer the therapies.

Cogent Biosciences, Inc. (COGT) Valuation Context

Valued at $5.76B, COGT is classified as a mid-cap stock. Analyst price targets span from $45.00 to $55.00, with a consensus of $51.75. At the current price of $33.72, that implies approximately 53% upside potential. Relative to its peer group, COGT's quantitative score of 55/100 is below the peer average of 81/100.

COGT Revenue & Earnings Trend

In Q2 FY2026, COGT generated $0 in top-line revenue. The company recorded a net loss of $96.4M, with diluted EPS of $-0.56. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, COGT averaged $-0.59 in diluted EPS.

Company Profile

Cogent Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, United States.

Return on equity for Cogent Biosciences, Inc. stands at -85.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -38.1%, showing how much profit it generates from its asset base. A current ratio of 15.14 indicates the company holds enough short-term assets to cover its near-term obligations.

Cogent Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.86 places it in the safe zone, indicating low near-term bankruptcy risk.

Cogent Biosciences, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses.

Over the past six months, Cogent Biosciences, Inc. insiders filed 19 SEC Form 4 transactions — 7 sales and 12 purchases. On net that is roughly 35K shares acquired (about $240.8M) — insiders putting money in tends to read as conviction.

COGT Financials

COGT Latest News

COGT Analyst Consensus

COGT MoonshotScore

Latest Cogent Biosciences, Inc. Analysis

Cogent Biosciences, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources